Pulmonary infections are the leading cause of mortality in cystic fibrosis (CF) patients. Pseudomonas aeruginosa is the most commonly isolated organism from these infections and the prevalence of multidrug-resistant (MDR) strains of this bacterium is increasing rapidly.
Agile Sciences is currently evaluating a lead compound as a combination treatment along with tobramycin for this application. The program is currently evaluating aerosol delivery of the compound in a mouse model of cystic fibrosis. The project has been funded by a Phase II STTR grant from the NIH.
Bacteria are developing resistance to all known antibiotics and the rate of resistance development is occurring at a faster pace than pharmaceutical companies are able to introduce new drugs to market.
Agile Sciences’ 2-AI molecules have the potential to overcome bacterial resistance elements so as to restore the efficacy of multiple antibiotics that are currently inactive against MDR Gram-negative bacterial strains. The 2-AI molecules are widely active across multiple bacterial species, and are able to effectively overcome multiple antibiotic resistance mechanisms.
Chronic wounds are defined as those that fail to heal through an orderly and timely reparative process. Approximately 6.5 million patients are afflicted with chronic wounds in the U.S. each year, and the burden is growing rapidly due to the increasing aging population and the rise in the incidence of diabetes.
Agile Sciences is evaluating the effectiveness of a lead 2-AI compound in combination with silver for use as a topical treatment for chronic wound infections. The lead compound has been shown to have anti-biofilm activities against Staphylococcus aureus and Pseudomonas aeruginosa, two bacteria that are often responsible for chronic wound infections.